An update on the role of daratumumab in the treatment of multiple myeloma.

@article{Costello2017AnUO,
  title={An update on the role of daratumumab in the treatment of multiple myeloma.},
  author={Caitlin L Costello},
  journal={Therapeutic advances in hematology},
  year={2017},
  volume={8 1},
  pages={28-37}
}
Monoclonal antibodies (mAbs) have emerged as a promising new drug class for the treatment of multiple myeloma (MM). Daratumumab (DARA), a CD38 mAb, has demonstrated safety, tolerability and activity in a range of clinical trials, both as monotherapy and in combination strategies for MM. The favorable efficacy results in heavily pretreated patients with advanced MM have provided the rationale for the investigation of DARA in a number of ongoing and future phase II and III trials. The general… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Daratumumab ( DARA ) , a CD38 mAb , has demonstrated safety , tolerability and activity in a range of clinical trials , both as monotherapy and in combination strategies for MM .
Daratumumab ( DARA ) , a CD38 mAb , has demonstrated safety , tolerability and activity in a range of clinical trials , both as monotherapy and in combination strategies for MM .
Daratumumab ( DARA ) , a CD38 mAb , has demonstrated safety , tolerability and activity in a range of clinical trials , both as monotherapy and in combination strategies for MM .
All Topics

Statistics

0102020172018
Citations per Year

Citation Velocity: 7

Averaging 7 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.